Shin and colleagues found an increase in BDNF serum levels in patients with mild cognitive impairment (MCI), a cognitive decline strongly associated to AD progression, whereas BDNF concentrations decreased in severe AD, supporting the hypothesis that BDNF was up-regulated only in an early preclinical stage of the pathology [153]. This evidence concerns the gene BDNF and Alzheimer disease.